Stuttgart
14.10.25 | 07:57
0,064 Euro
0,00 % 0,000
1-Jahres-Chart
5-Tage-Chart
| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 0,053 | 0,074 | 23:00 | |
| 0,060 | 0,066 | 21:53 |
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Fr | Hemostemix Inc (2): Hemostemix applies for vascular dementia study approval | 4 | Stockwatch | ||
| Do | Hemostemix Inc.: Hemostemix Files for Ethics Approval of its Study of Vascular Dementia | 280 | Newsfile | Calgary, Alberta--(Newsfile Corp. - October 9, 2025) - Hemostemix (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) ("Hemostemix" or the "Company") is pleased to announce it has filed its Institutional Review... ► Artikel lesen | |
| Mi | Hemostemix Inc (2): Hemostemix receives $330,000 lead order for placement | 2 | Stockwatch | ||
| 07.10. | Hemostemix Inc.: Hemostemix's Insider Lead Order of $330,000 Private Placement | 272 | Newsfile | Calgary, Alberta--(Newsfile Corp. - October 7, 2025) - Hemostemix (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) ("Hemostemix" or the "Company") is pleased to announce a lead order of $330,000 for a non brokered... ► Artikel lesen | |
| 24.09. | Hemostemix Inc (2): Hemostemix files FDA trial for ACP-01 stem therapy | 2 | Stockwatch | ||
| HEMOSTEMIX Aktie jetzt für 0€ handeln | |||||
| 23.09. | Hemostemix Inc.: Hemostemix Files FDA Submission for Basket Protocol (Filing 1517) to Advance ACP-01 (VesCell) Across Multiple Ischemic and Vascular Indications Simultaneously | 327 | Newsfile | Calgary, Alberta--(Newsfile Corp. - September 23, 2025) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0), the leading autologous (patient's own) stem cell therapy company offering VesCell (ACP-01)... ► Artikel lesen | |
| 17.09. | Hemostemix Inc.: Hemostemix to Present at Life Science Investor Forum | 164 | Newsfile | Calgary, Alberta--(Newsfile Corp. - September 17, 2025) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0), the leading autologous (patient's own) stem cell therapy company offering VesCell (ACP-01)... ► Artikel lesen | |
| 16.09. | Hemostemix Inc.: Hemostemix to Present Its Clinical Data of the Treatment of Severe Angina | 330 | Newsfile | Calgary, Alberta--(Newsfile Corp. - September 16, 2025) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0), the leading autologous (patient's own) stem cell therapy company offering VesCell (ACP-01)... ► Artikel lesen | |
| 12.09. | Hemostemix Inc (2): Hemostemix two million shares for debt | 2 | Stockwatch | ||
| 11.09. | Hemostemix Inc (2): Hemostemix to issue two million shares for debt | 2 | Stockwatch | ||
| 10.09. | Hemostemix Inc.: Hemostemix Announces TSXV Approval of Debt Settlement at $0.20 per Share | 430 | Newsfile | Calgary, Alberta--(Newsfile Corp. - September 10, 2025) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) ("Company"), the leading autologous (patient's own) stem cell therapy company offering... ► Artikel lesen | |
| 10.09. | Hemostemix Inc (2): Hemostemix arranges $280,594 private placement | 2 | Stockwatch | ||
| 09.09. | Hemostemix Inc (2): Hemostemix launches corporate website | 1 | Stockwatch | ||
| 09.09. | Hemostemix announces $280K non-brokered private placement | 3 | Seeking Alpha | ||
| 09.09. | Hemostemix Inc.: Hemostemix Announces Private Placement | 315 | Newsfile | Calgary, Alberta--(Newsfile Corp. - September 9, 2025) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0), the leading autologous (patient's own) stem cell therapy company offering VesCell (ACP-01)... ► Artikel lesen | |
| 09.09. | Hemostemix Inc.: Hemostemix Launches Enhanced HubSpot-Powered Websites to Support Global Marketing & Sales of ACP-01 for No-Option Patients | 319 | Newsfile | Calgary, Alberta--(Newsfile Corp. - September 9, 2025) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0), the leading autologous (patient's own) stem cell therapy company offering VesCell (ACP-01)... ► Artikel lesen | |
| 05.09. | Hemostemix Inc (2): Hemostemix rolls out VesCell.Health in Florida | 2 | Stockwatch | ||
| 04.09. | Hemostemix Inc.: Hemostemix's VesCell.Health Launched in Florida | 346 | Newsfile | Calgary, Alberta--(Newsfile Corp. - September 4, 2025) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0), the leading autologous (patient's own) stem cell therapy company offering VesCell (ACP-01)... ► Artikel lesen | |
| 04.09. | Hemostemix Inc (2): Hemostemix cheers 17 "years of line gained" by Lindeman | 16 | Stockwatch | ||
| 03.09. | Hemostemix Inc.: Howie's 17+ Years After VesCell: Following Hemostemix's Heart Patients | 341 | Newsfile | Calgary, Alberta--(Newsfile Corp. - September 3, 2025) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0), the leading autologous (patient's own) stem cell therapy company offering VesCell (ACP-01)... ► Artikel lesen |
1 2 3 4 5 Weiter >>
88 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| EVOTEC | 6,586 | -2,95 % | Evotec Aktie: Strohfeuer oder klappt es diesmal? | Die Evotec Aktie zeigt Stärke - aber diesmal auch für eine längere Zeit? Seit dem 26. September hat sich die TecDAX-notierte Biotech-Aktie von 5,882 Euro um mehr als einen Euro verteuert. Am gestrigen... ► Artikel lesen | |
| QIAGEN | 40,610 | -0,84 % | QIAGEN N.V. to Release Results for Q3 2025 and Hold Webcast | QIAGEN N.V. (NYSE: QGEN) (Frankfurt Stock Exchange: QIA) today announced plans to release results for the third quarter of 2025.
Press release date time: Tuesday, November 4, shortly after 22:05... ► Artikel lesen | |
| PAION | 0,017 | -24,11 % | Interne Dokumente des Wirtschaftsministeriums zeigen: So lief der umstrittene Verkauf der Paion AG an chinesische Investoren ab | ||
| VALNEVA | 4,422 | -1,07 % | Valneva: Prognose runter - und nun? | Die Aktie des Impfstoffherstellers Valneva stand am Montag deutlich unter Druck. Und auch am heutigen Dienstag verzeichnet das Papier im frühen Handel weitere leichte Verluste. Das Unternehmen musste... ► Artikel lesen | |
| EPIGENOMICS | 0,960 | 0,00 % | PTA-AFR: Epigenomics AG: Vorabbekanntmachung über die Veröffentlichung von Finanzberichten gemäß §§ 114-117 WpHG | DJ PTA-AFR: Epigenomics AG: Vorabbekanntmachung über die Veröffentlichung von Finanzberichten gemäß §§ 114-117 WpHG
Vorabbekanntmachung Finanzberichte gemäß ---- 114-117 WpHG
Epigenomics... ► Artikel lesen | |
| NOVAVAX | 7,665 | +2,79 % | Novavax-Aktie steigt nach Verkaufsforderung von Großaktionär | ||
| STRYKER | 318,60 | +0,98 % | 6 Analysts Have This To Say About Stryker | ||
| CRISPR THERAPEUTICS | 60,50 | +1,68 % | Citizens bestätigt "Market Outperform"-Rating für CRISPR Therapeutics | ||
| CORE ONE LABS | 0,079 | -100,00 % | XFRA DELETION OF INSTRUMENTS FROM BOERSE FRANKFURT - 22.09.2025 | The following instruments on Boerse Frankfurt do have their last trading day on 22.09.2025Die folgenden Instrumente in Boerse Frankfurt haben ihren letzten Handelstag am 22.09.2025ISIN NameAU000000PEK2 PEAK... ► Artikel lesen | |
| OCUGEN | 1,411 | +2,36 % | Ocugen, Inc. and Kwangdong Pharmaceutical Co., Ltd. Complete License Agreement of OCU400 Modifier Gene Therapy for Retinitis Pigmentosa in Korea | Upfront fees and near-term development milestone payments totaling up to $7.5 millionPotential sales milestones of $180 million or more in first 10 years of commercializationRoyalties equaling 25%... ► Artikel lesen | |
| MAINZ BIOMED | 1,535 | -1,29 % | EQS-News: Mainz BioMed N.V.: Mainz Biomed berichtet Topline-Ergebnisse aus der Machbarkeitsstudie zum Biomarker-Panel im Rahmen seines Bauchspeicheldrüsenkrebs-Projekts | Emittent / Herausgeber: Mainz BioMed N.V.
/ Schlagwort(e): Studienergebnisse
Mainz Biomed berichtet Topline-Ergebnisse aus der Machbarkeitsstudie zum Biomarker-Panel im Rahmen... ► Artikel lesen | |
| MINERALYS THERAPEUTICS | 42,800 | -0,58 % | Mineralys Therapeutics: Aktie erreicht Rekordhoch von 41,11 USD | ||
| TARSUS PHARMACEUTICALS | 69,83 | -0,72 % | Tarsus Pharmaceuticals, Inc: Tarsus Reports Second Quarter 2025 Financial Results and Recent Business Achievements | Record quarterly net product sales of $102.7 million achieved within two years of our XDEMVY® launch, an increase of 152% year over year Direct-To-Consumer campaign has activated new patients, expanded... ► Artikel lesen | |
| BEAM THERAPEUTICS | 25,420 | +0,12 % | Jefferies stuft Beam Therapeutics auf "Buy": Kommende Katalysatoren im Fokus | ||
| ARCELLX | 87,33 | +1,28 % | Arcellx, Inc.: Arcellx Announces Its Participation at TD Cowen's 6th Annual Oncology Innovation Summit and Its Investor Event During EHA2025 | Arcellx, Inc. (NASDAQ: ACLX), a biotechnology company reimagining cell therapy through the development of innovative immunotherapies for patients with cancer and other incurable diseases, today announced... ► Artikel lesen |
HEMOSTEMIX INC gehört der Branche Biotechnologie an. Die relative Kursveränderung beträgt aktuell 0,00 % bei einem Aktienkurs von 0,064 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu HEMOSTEMIX INC finden Sie auf Wallstreet Online.